
	Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine (&quot;Eltoprazine&quot;), a phase 2b ready indication for Parkinson&#39;s Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (&quot;LymPro Test(R)&quot;) for Alzheimer&#39;s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (&quot;MANF&quot;) and is developing MANF-based products as treatments for brain disorders.

	&nbsp;

	Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson&#39;s disease (&quot;NuroPro&quot;) and the discovery of neurotrophic factors (&quot;PhenoGuard&quot;).
